Newswise — December 29, 2022 — In cancer patients with neutropenic fever, delaying antibiotic treatment past 60 minutes from the time of fever detection does not reduce the short-term chance of survival, according to a study in the American Journal of Medical Quality. The journal is published in the Lippincott portfolio by Wolters Kluwer.
Neutropenia—low levels of white blood cells called neutrophils, which fight infection—develops in more than 80% of patients who receive chemotherapy for a blood cancer. It occurs because chemotherapy destroys neutrophils along with tumor cells.
A fever in a patient with neutropenia is considered a medical emergency, according to Adam Binder, MD, of Thomas Jefferson University Hospital in Philadelphia, and colleagues. The fever signals a severe decrease in neutrophils and therefore a compromised ability of the immune system to ward off infections. Neutropenic fever is defined as a temperature of at least 101°, or a sustained temperature of at least 100.4° for an hour or more.
The Infectious Disease Society of America and the American Society of Clinical Oncology have both published guidelines for treating outpatients who have neutropenic fever. Both organizations call for administering an intravenous antibiotic within 60 minutes after the fever is detected. The recommendation about antibiotics is also often applied to the treatment of hospital inpatients, but there’s no clear evidence that’s appropriate.
Comparing inpatients who did or did not receive antibiotics during the recommended treatment window
Dr. Binder and his colleagues looked back at data on 187 patients at their hospital who had developed neutropenic fever. Their main goal was to see whether delays in antibiotic treatment affected short-term survival.
Only 14% of patients received antibiotics within 60 minutes of developing neutropenic fever. Their survival rate 6 months later wasn’t significantly better than the survival rate of patients who received antibiotics later than recommended.
Further analysis identified several factors that had a statistically significant association with the risk of death:
A possible explanation for the last finding, the researchers say, is that patients who received antibiotics within 40 minutes "had other symptoms that yielded a concerning clinical picture, thus leading to a timelier administration of antibiotics, but ultimately a worse clinical outcome."
Guidelines for treatment of outpatients may not apply to hospitalized patients
Even a delay of more than 4 hours wasn’t long enough to affect survival, Dr. Binder and his colleagues determined. That result is consistent with information from previous studies of inpatients, they say.
The authors believe existing treatment guidelines are appropriate for patients with neutropenic fever who are treated in a physician’s office or an emergency department, but other factors must be considered for patients who have been admitted to a hospital. "Unlike neutropenic fever patients presenting to the emergency department, where true time to antibiotic administration may often be many hours or even days before arrival, a few hours long [delay] in the hospital may not be sufficiently long enough to cause significant patient harm."
About the American Journal of Medical Quality
The American Journal of Medical Quality (AJMQ) is the official journal of the American College of Medical Quality. AJMQ is focused on keeping readers informed of the resources, processes, and perspectives contributing to quality health care services. This peer-reviewed journal presents a forum for the exchange of ideas, strategies, and methods in improving the delivery and management of health care.
About the American College of Medical Quality
The American College of Medical Quality (ACMQ) is the organization for healthcare professionals responsible for providing leadership in quality and safety outcomes, who want or need the tools, experience, and expertise to improve the quality and safety of patient care. Membership in ACMQ provides a gateway to resources, programs, and professional development opportunities and a greater recognition of quality issues by the entire healthcare field.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2021 annual revenues of €4.8 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.